Trial Profile
A Multicenter, Multinational, Extension Study to Evaluate the Long Term Safety and Efficacy of Intracerebroventricular AX 250 in Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Tralesinidase alfa (Primary)
- Indications Mucopolysaccharidosis III
- Focus Adverse reactions; Therapeutic Use
- Sponsors Allievex Corporation; BioMarin Pharmaceutical
- 20 Dec 2023 This trial has been suspended in Germany, according to European Clinical Trials Database record.
- 08 Jul 2020 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2020 This trial is discontinued in Spain, according to European Clinical Trials Database record.